AGTC - Applied Genetic Technologies Corporation
| Previous Close | 2.7100 |
| Open | 2.7000 |
| Bid | 2.1900 x 1000 |
| Ask | 0.0000 x 1100 |
| Day's Range | 2.6500 - 2.7600 |
| 52 Week Range | 2.2600 - 4.9500 |
| Volume | 151,779 |
| Avg. Volume | 143,092 |
| Market Cap | 49M |
| Beta (5Y Monthly) | 2.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8210 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.42 |
- Thomson Reuters StreetEvents
Edited Transcript of AGTC earnings conference call or presentation 12-Nov-19 9:30pm GMT
Q1 2020 Applied Genetic Technologies Corp Earnings Call
- Benzinga
The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...
- GlobeNewswire
AGTC Announces Departure of Chief Medical Officer, Company on Track to Announce XLRP and ACHM Data in January 2020
Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Theresa Heah, M.D., Chief Medical Officer, has resigned from the company to pursue other opportunities. Given that the clinical results for the upcoming data releases are still being processed at external vendors and not yet available for internal review, Dr. Heah’s resignation does not relate to any knowledge of pending results. Dr. Heah has agreed to stay with the company until the end of the year to support the up-coming data analysis.
- Zacks
Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -10.34% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2019
Company to host R&D Day on January 28, 2020, in New York GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 12, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC),.
- GlobeNewswire
AGTC to Host First Quarter Results Conference Call and Webcast on November 12, 2019
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 06, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
- GlobeNewswire
AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Program and Reports Compelling Preclinical Data Supporting the Potential of its Dual-Vector Technology
Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has identified Stargardt disease as the second ophthalmology program in its previously announced preclinical pipeline expansion, which also includes a program targeting the dry form of age-related macular degeneration (AMD). The company is also reporting proof-of-concept expression data for its Stargardt disease gene therapy candidate in non-human primates (NHPs).
- Simply Wall St.
We Think Applied Genetic Technologies (NASDAQ:AGTC) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
AGTC Presents Data Demonstrating Efficiency of its AAV Vectors for Ocular Gene Therapy Even in the Presence of Anti-AAV Antibodies
Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today reported new data from non-clinical studies evaluating the effect of pre-existing anti-AAV antibodies on the transduction and expression efficiency of AAV vectors. Results show that the presence of neutralizing antibodies (NAbs) to AAV in the serum or in the eye did not affect gene delivery, gene expression, or inflammation following ocular administration of AAV vectors. “Preexisting immunity to AAV remains a challenge for many AAV gene therapies due to the high prevalence of AAV in the general population,” said Mark Shearman, Ph.D., Chief Scientific Officer of AGTC and lead author on the poster.
- GlobeNewswire
AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss
GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human.
- Thomson Reuters StreetEvents
Edited Transcript of AGTC earnings conference call or presentation 26-Sep-19 8:30pm GMT
Q4 2019 Applied Genetic Technologies Corp Earnings Call
- Benzinga
Applied Genetic Notches Sell-Side Upgrade After Releasing Interim Study Data
Biotechnology company Applied Genetic Technologies Corp (NASDAQ: AGTC ) presented interim six-month data Thursday for the Phase 1/2 XLRP program in X-linked retinitis pigmentosa, turning BMO Capital ...
- Zacks
Applied Genetic Technologies (AGTC) Reports Q4 Loss, Lags Revenue Estimates
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -13.73% and -42.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2019
Company announces promising topline six-month dose escalation data from its ongoing Phase 1/2 clinical trials for X-linked retinitis pigmentosa (XLRP) Preliminary three-month.
- ACCESSWIRE
Applied Genetic Technologies Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / September 26, 2019 / Applied Genetic Technologies Corp. (NASDAQ: AGTC ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on September ...
- GlobeNewswire
AGTC to Present at Upcoming Conferences
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 25, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
- Zacks
Analysts Estimate Applied Genetic Technologies (AGTC) to Report a Decline in Earnings: What to Look Out for
Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 26, 2019
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 18, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
- Simply Wall St.
How Many Applied Genetic Technologies Corporation (NASDAQ:AGTC) Shares Do Institutions Own?
The big shareholder groups in Applied Genetic Technologies Corporation (NASDAQ:AGTC) have power over the company...
- GlobeNewswire
Italian Achromatopsia Association Increases Global Awareness of Achromatopsia, a Rare Genetic Eye Disease, With an Expedition to Pingelap, the Island of the Color Blind
The Italian Achromatopsia Association (IAA) today announced that it is organizing a trip to Pingelap, a remote Micronesian atoll in the South Pacific, also known as the “Island of the Color Blind.” While the incidence of achromatopsia, a rare inherited retinal disease (IRD), in the general population is 1 in every 30,000 individuals, the condition is found in between 10 and 30 percent of Pingelap’s population. The trip was made possible in part by a number of sponsors, including Applied Genetic Technologies Corporation (AGTC), a biotechnology company that is committed to developing transformational genetic therapies for patients suffering from rare diseases, including achromatopsia.
- GlobeNewswire
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 14, 2019
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 07, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
- Zacks
Alexion (ALXN) Q2 Earnings Beat Estimates, Guidance Raised
Alexion (ALXN) beats both earnings and sales estimates in the second quarter of 2019 and raises 2019 guidance.
- GlobeNewswire
AGTC Completes Enrollment of Third Group in the Dose Escalation Portion of the Achromatopsia CNGA3 Phase 1/2 Clinical Study
Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has completed enrollment of the third group in the dose escalation portion of its Phase 1/2 clinical trial evaluating the safety and efficacy of subretinal injection of (rAAV2tYF-PR1.7-hCNGA3) for the treatment of achromatopsia (ACHM) caused by mutations in the CNGA3 gene. “This achievement is another demonstration of our continued progress in the clinical development of our three product candidates for the treatment of X-linked retinitis pigmentosa and achromatopsia due to mutations in the CNGA3 or CNGB3 gene,” said Sue Washer, president and CEO of AGTC.
